Evaluation of Clinical Management and Outcome in High-Risk or Recurrent Endometrial Cancer

Evaluation of Clinical Management and Outcome in High-Risk or Recurrent Endometrial Cancer - QS-Endometrium

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038045

Enrollment

600

Registered

2025-10-02

Start date

2026-01-27

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C54.1

Interventions

Group 1: The routine treatment and clinical outcomes of patients diagnosed with high-risk or recurrent endometrial cancer between 2023 and 2025 in gynecological cancer centers of the AGO study group w

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Primarily high-risk or recurrent endometrial cancer - High-risk is defined according to ESGO guidelines 2025, integrating FIGO 2023 into molecular subtyping (Concin N. Lancet Oncol et al. 2025) or - According to FIGO 2009 All stages and all histologies with p53 (with p53 aberrant tumor biology and myometrial invasion. All stages with serous od undifferentiated carcinoma including carcinosarcoma with myometrial invasion All stage III or IV at first diagnosis (regardless of residual tumor, histology and molecular subtype) or - recurrent endometrial cancer - Treatment in participating centers between 07/2023 and 07/2025

Exclusion criteria

Exclusion criteria: True sarkomas

Design outcomes

Primary

Measure	Time frame
Description of the landscape of treatment realities in high-risk and recurrent endometrial cancer	—

Secondary

Measure	Time frame
1. Progression-free Survival (PFS): time interval (months) from diagnosis of high, risk, primarily advanced or recurrent endometrial cancer to second recurrence. In case of lost-to-follow-up patients, the last date of contact is used as censored progression free survival time. 2. 1st Overall Survival (OS): time interval (months) from the first diagnosis of endometrial cancer to the death of the patient (exact survival time). In case of alive and lost-to-follow-up patient, the last date of contact is used as censored survival time. 3. 2st Overall Survival (OS_2L): time interval (months) from the first diagnosis of recurrent endometrial cancer to the death. In case of alive and lost-to-follow-up patient, the last date of contact is used as censored survival time.	—

Measure

Time frame

1. Progression-free Survival (PFS): time interval (months) from diagnosis of high, risk, primarily advanced or recurrent endometrial cancer to second recurrence. In case of lost-to-follow-up patients, the last date of contact is used as censored progression free survival time. 2. 1st Overall Survival (OS): time interval (months) from the first diagnosis of endometrial cancer to the death of the patient (exact survival time). In case of alive and lost-to-follow-up patient, the last date of contact is used as censored survival time. 3. 2st Overall Survival (OS_2L): time interval (months) from the first diagnosis of recurrent endometrial cancer to the death. In case of alive and lost-to-follow-up patient, the last date of contact is used as censored survival time.

—

Countries

Germany

Contacts

Public ContactLars Hanker

Klinik für Frauenheilkunde und Geburtshilfe Universitätsklinikum Münster (UKM)

lars.hanker@ukmuenster.de49 251 83-48201

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026